Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 107-128

  Moeremans, Karen ^a   Annemans, Lieven ^b   Löthgren, Mickael ^c   Allegri, Gabriele ^d   Wyffels, Veronique ^e   Hemmet, Lindsay ^f   Caekelbergh, Karin ^a   Smets, Erik ^g  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c Janssen Cilag AB   (Sweden)

^d Janssen Cilag SpA Italia   (Italy)

^e Janssen Cilag EMEA Belgium   (Belgium)

^f Tibotec a division of Janssen Cilag Ltd   (United Kingdom)

^g JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; PROTEINASE INHIBITOR; RITONAVIR PLUS TIPRANAVIR; TIPRANAVIR; VIRUS RNA;

ARTICLE; BELGIUM; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; ITALY; LIFESPAN; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SENSITIVITY ANALYSIS; SWEDEN; UNITED KINGDOM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; ITALY; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR; RNA, VIRAL; SULFONAMIDES; SWEDEN;

EID: 78650717778     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587480-000000000-00000     Document Type: Article

References (94)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362: 22-9
3. Hamers FF, Downs AA. The changing face of the HIV epidemic in western Europe: What are the implications for public health policies? Lancet 2004; 364: 83-94
4. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19
5. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-73
6. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiviral Ther 2002; 7: 257-66
7. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 2006; 6: 171-7
8. Beck EJ, Mandalia S. The cost of HIV treatment and care in England since HAART - part 1. Br J Sex Med 2006; 27: 19-23
9. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA study group. J Infect Dis 2004; 190: 1947-56
10. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: Multicentre cohort study. BMJ 2005; 330: 695
11. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIVinfected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487-503
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2009 Dec 1 [online]. Available from URL: Http://www.aidsinfo.nih.gov/ContentFiles/Adult andAdolescentGL.pdf [Accessed 2009 Dec 10]
13. Hammer SM, Saag MS, Schechter M, et al. Treatment for Adult HIV Infection: 2006 recommendations of the International AIDS Society - USA Panel. JAMA 2006; 296: 827-43
14. Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201-7
15. Ledergerber B, Lundgren JD,Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62
16. Gazzard B, BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIVinfected adults with antiretroviral therapy (2005). HIV Med 2005 Jul; 6 Suppl. 2: 1-61
17. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-9
18. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-21
19. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78
20. U.S. Food and Drug Administration (FDA). Press announcements: FDA approves new HIV treatment for patients who do not respond to existing drugs; 2006. Jun 23 [online]. Available from URL: Http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108676.htm [Accessed 2009 Dec 10]
21. European Medicines Agency (EMEA). Press release: Meeting highlights from the Committee for Medicinal Products for Human Use; 2006 Dec 11-14 [online]. Available from URL: Http://www.emea.europa.eu/pdfs/human/press/pr/50697706en.pdf [Accessed 2009 Dec 10]
22. European Commission. Community register of medicinal products for human use: Prezista; [online]. Available from URL: Http://ec.europa.eu/enterprise/ pharmaceuticals/reg ister/h380.htm [Accessed 2009 Dec 10]
23. Mauskopf J, Brogan A, Smets E, et al. Cost-effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients [abstract P51]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow, UK
24. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 92-6
25. Tibotec BVBA. Darunavir: 2.5 clinical overview. Document 39881. Tibotec Therapeutics, Bridgewater, NJ, USA. Confidential information, 2005 Dec 7
26. Euroguidelines Group. Summary European guidelines for the clinical management and treatment of HIV infected adults in Europe [summary, pocket version]. 10th European AIDS Conference (EACS) Symposium; 2005 Nov 10-17; Dublin, Ireland
27. Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression. Curr Opin HIV AIDS 2006; 1: 43-9
28. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487-94
29. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41: 361-72
30. Hicks C, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised openlabel trials. Lancet 2006; 368: 466-75
31. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168-75
32. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 Tlymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-95
33. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-15
34. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17: 963-9
35. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004; 36: 702-13
36. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: A comparison with the general population. AIDS 2004; 18: 89-97
37. Mauskopf J, Brogan A, Martin S, et al. Cost-effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1- infected adults in the USA. PharmacoEconomics 2010; 28 Suppl. 1: 83-105
38. Tibotec Pharmaceuticals. Data on file, 2006
39. Cahn P,RESIST 2 Study Team. 24-week data fromRESIST 2: Phase 3 study of the efficacy and safety of background therapy plus tipranavir/ritonavir (TPV/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatmentexperienced HIV+ patients [abstract PL14.3]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow, UK
40. Pozniak A, Jayaweera D, Hoy J, et al. Efficacy of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the POWER 1 and 2 trials [abstract P7.2/07]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
41. Hicks C, RESIST 1 Study Team. A Phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data [abstract 3726]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 31-Nov 2;Washington, DC, USA
42. Hicks C, RESIST 1 Study Team. Phase 3 comparison of TPV/r and standard-of-care boosted-comparator PI (CPI/r) at 24 weeks [abstract H-1137a]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco, CA, USA
43. World Health Organization. Mortality database: Tables. Italy; 2004 [online]. Available from URL: Http://www.who.int/healthinfo/morttables/en/index. html [Accessed 2009 Dec 10]
44. Statistics Sweden. Tables on the population in Sweden 2005. Official Statistics of Sweden; 2006 [online]. Available from URL: Http://www.scb.se/ statistik/-publikationer/BE0101-2005A01-BR-BE0106TAB.pdf [Accessed 2009 Dec 10]
45. Belgian National Institute of Statistics (NIS). Démographie mathématique: Tables de mortalité ; 2001 [online]. Available from URL: Http://statbel.fgov.be/fr/binaries/p238y2001-fr-tcm326-39345.pdf [Accessed 2009 Dec 10]
46. UK Government Actuary's Department. Life tables; 2005 [online]. Available from URL: Http://www.gad.gov.uk/Demography%20Data/Life%20Tables/index.html [Accessed 2009 Dec 10]
47. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5: 294-304
48. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108
49. Hill AM, Clotet B, Johnson M, et al. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: The POWER experience. PharmacoEconomics 2010; 28 Suppl. 1: 69-81
50. Caekelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage [abstract P19.5/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
51. Tramarin A, Campostrini S, PostmaMJ, et al. Amulticentre study of patient survival, disability, quality of life and cost of care: Among patients with AIDS in northern Italy. PharmacoEconomics 2004; 22: 43-53
52. Istituto Nazionale di Statistica. Indices of Consumer Prices; [online]. Available from URL: Http://www.istat.it [Accessed 2009 Dec 10]
53. Ghatnekar O, GisslénM, Hjortsberg C, et al. Medical resource use and cost of HIV-related care in the HAART-era at a university clinic in Sweden [abstract P19.10/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
54. Petrou S,Dooley M, Whitaker L, et al. The economic cost of caring for people with HIV infection and AIDS in England and Wales. PharmacoEconomics 1996; 9: 332-40
55. Personal Social Services Research Unit (PSSRU). Unit costs of health and social care 2008. Inflation indices; [online]. Available from URL: Http://www.pssru.ac.uk/uc/uc2008 contents.htm [Accessed 2009 Dec 10]
56. Statistics Belgium. Directorate-general statistics and economic information; [online]. Available from URL: Http://statbel.fgov.be [Accessed 2009 Dec 10]
57. Statistics Sweden. Consumer price index: Tables and charts; [online]. Available from URL: Http://www.scb.se/Pages/TableAndChart-33907.aspx [Accessed 2009 Dec 10]
58. Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: Recommendations from the Italian group of pharmacoeconomic studies. Drug Information J 2001; 35: 189-201
59. Tandvårds- och läkemedelsförmånsverket (TLV). General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). 2003 Apr 24 [online]. Available from URL: Http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf [Accessed 2009 Dec 10]
60. Cleemput I, Crott R, Vrijens F, et al. Voorlopige richtlijnen voor farmaco-economisch onderzoek in België Brussel: Federaal Kenniscentrum voor de gezondheidszorg (KCE); KCE Reports vol. 28A. Ref. D/2006/10.273/10; 2006 [online]. Available from URL: Www.kce.fgov.be/Download. aspx?ID=494 [Accessed 2009 Dec 10]
61. Cook J, Dasbach E, Coplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: Application to a clinical trial. AIDS Res Hum Retroviruses 1999; 15: 499-508
62. Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22: 27-38
63. King Jr JT, Justice AC, Roberts MS, et al. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 2003; 23: 9-20
64. World Health Organization (WHO). Table: Threshold values for intervention cost-effectiveness by Region; [online]. Available from URL: Http://www.who.int/choice/costs/CER-levels/en/index.html [Accessed 2009 Dec 10]
65. Towse A. What is NICE's threshold? An external view. Chapter 2. In: Devlin N, Towse A, editors. Cost effectiveness thresholds: Economic and ethical issues. London: King's Fund/Office for Health Economics, 2002
66. Birch S, Gafni A. On being NICE in the UK: Guidelines for technology appraisal for the NHS in England and Wales. Health Econ 2002; 11: 185-91
67. Birch S, Gafni A. The 'NICE' approach to technology assessment: An economics perspective. Health Care Manag Sci 2004; 7: 35-41
68. Gafni A, Birch S, NICE; National Health Service. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmaco- Economics 2003; 21: 149-57
69. Stoll M, Schulte E, Claes C, et al. The cost of an HIV patient. Lack of funds for optimal treatment? [Article in German]. MMW Fortschr Med 2001; 143 Suppl. 1: 72-7
70. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost ofHIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 2001; 13: 733-41
71. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817-23
72. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101-5
73. Hornberger J, Green J, Wintfeld N, et al. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. HIV Clin Trials 2005; 6: 92-102
74. European Medicines Evaluation Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report (EPAR): Aptivus. EMEA/H/C/631; 2007 [online]. Available from URL: Http://www.emea. europa.eu/humandocs/PDFs/EPAR/ap tivus/32004705en1.pdf [Accessed 2009 Dec 10]
75. Hill A, Moyle G. Relative antiviral efficacy of ritonavirboosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-64
76. Gathe J, DeJesus E, Falcon R, et al. Examination of factors influencing response to darunavir combined with low-dose ritonavir in POWER 1, 2, and 3: Pooled 48-week analysis [abstract 66]. Frontiers in Drug Development for Antiretroviral Therapies; 2006 Dec 10-14; Cancun, Mexico
77. Decock RC, Depoorter AM, De Graeve D, et al. Direct costs of health care for HIV/AIDS patients in Belgium. AIDS Care 2001; 13: 721-31
78. Stoll M, Claes C, Schulte E, et al. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res 2002; 7: 463-71
79. Levy A, Annemans L, Tramarin A, et al. The impact of disease stage on direct medical costs of HIV infection: A review of the international literature. PharmacoEconomics 2010; 28 Suppl. 1: 35-47
80. Lalezari J, Goodricj J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada [abstract 104bLB]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles, CA, USA
81. Madruga JV, Cahn P, Grinsztejn B, on behalf of the DUET- 1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results froma randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38
82. Lazzarin A, Campbell T, Clotet B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1- infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48
83. Kahn JO, Lagakos SW, Richman DD. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 1992; 327: 581-7
84. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 1997; 349: 1413-21
85. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348 : 283-91
86. Lacey L, Youle M, Trueman P, et al. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective. PharmacoEconomics 1999; 15 Suppl. 1: 39-53
87. Food and Drug Administration (FDA), Division of Antiviral Drug Products. Guidance for industry: Antiretroviral drugs using plasma HIV RNA measurements. Clinical considerations for accelerated and traditional approval, prepared by the: Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER), Appendix B; 2002 Oct
88. European Medicines Evaluation Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Draft: Guideline on the clinical development of medicinal products for the treatment of HIV infection. London,18 October 2007. EMEA/CPMP/EWP/633/02 Rev. 2; 2007 Oct 18 [online]. Available from URL: Http://www.emea. europa.eu/pdfs/human/ewp/063302enrev2.pdf [Accessed 2009 Dec 10]
89. Madruga JV, Berger D, McMurchieM, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir- ritonavir at 48 weeks in treatment-experienced, HIVinfected patients in TITAN: A randomised controlled phase III trial. Lancet 2007; 370: 49-58
90. Berger DS, Northland R, Scribner A, et al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at week 48 in TITAN [abstract P7.3/27]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
91. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97
92. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002 Dec 15; 31 Suppl. 3: S123-7
93. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naive, HIV-1-infected patients. Antivir Ther 2003; 8: 339-46
94. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235-42